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The most fundamental property of biomarkers is change. But changes are hard to maintain in plasma since it is strictly con-
trolled by homeostatic mechanisms of the body. There is no homeostatic mechanism for urine. Besides, urine is partly a filtra-
tion of blood, and systematic information can be reflected in urine. We hypothesize that change of blood can be reflected in 
urine more sensitively. Here we introduce the interference into the blood by two anticoagulants heparin or argatroban. Plasma 
and urine proteins were profiled by LC-MS/MS and then validated by Western blot in totally six SD female rats before and af-
ter the drug treatments. In argatroban treated group, with exactly the same experimental procedure and the same cutoff value 
for both plasma and urine proteins, 62 proteins changed in urine, only one of which changed in plasma. In heparin treated 
group, 27 proteins changed in urine but only three other proteins changed in plasma. Both LC-MS/MS and Western blot anal-
yses demonstrated drug-induced increases in transferrin and hemopexin levels in urine but not in plasma. Our data indicates 
that urine may serve as a source for more sensitive detection of protein biomarkers than plasma. 
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In comparison to plasma, urine has advantages as a source 
for biomarker discovery. First, urine can be collected 
non-invasively, frequently and in large quantities. Second, 
while plasma is generally obtained at a single time point, 
multiple urine samples can be collected over a period of 
time, allowing for an easier monitoring of time-dependent 
changes in biomarker levels. Third, proteolytic degradation 
may be complete prior to collection of urine [1,2] and be-
cause proteases are activated during blood collection [3], 
the urinary proteome shows much greater stability com-
pared with that of plasma. Urinary proteins, for example, 
show no significant changes when urine is stored for 3 d at 
4°C or for 6 h at room temperature [4,5]. The use of mem-
branes to store urinary proteins is simple and economical 
and facilitates biomarker research by making large-scale 
storage of clinical urinary samples possible [6].  
Most importantly, theoretical considerations suggest that 
urine may be a better source for biomarker discovery than 
plasma. Given that change is an essential property of a bi-
omarker, the strict homeostatic regulation of plasma com-
position would in theory act to correct any changes in bi-
omarker levels. While urine collects all waste from the body, 
it can accumulate more and bigger changes [7]. Therefore, 
urine serves not only as an ideal source of biomarker dis-
covery for diseases of the kidney and other tissues of the 
urogenital system but also as a potential source of infor-
mation on diseases in other physiological systems.  
We used two different anticoagulants (unfractionated 
heparin and argatrabon) to disrupt the blood coagulation 
status of adult female SD rats. Rat model was selected be-
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cause the urine from rats could be more easily collected 
than that from mice, since the volume and amount of uri-
nary proteins were higher than those of mice. We then 
compared the sensitivity of detection of changes in urine 
and plasma proteomic profiles in response to treatment with 
the drugs, to observe whether changes in urine can be more 
sensitively detected.  
1  Materials and methods 
1.1  Ethics statement 
Adult female Sprague-Dawley rats were purchased from the 
Institute of Laboratory Animal Science, Chinese Academy 
of Medical Science. The experiment was approved by Insti-
tutional Animal Care Use & Welfare Committee of Institute 
of Basic Medical Sciences, Peking Union Medical College 
(Animal Welfare Assurance Number: ACUC-A02-2013- 
015). All animals were kept with standard laboratory diet 
under controlled indoor temperature (22±1°C) and humidity 
(65%–70%). The study was performed consistently with 
guidelines developed by Institutional Animal Care Use & 
Welfare Committee of Institute of Basic Medical Sciences. 
1.2  Anticoagulants treatment of rats 
Six adult female Sprague Dawley rats were initially anaes-
thetized by an intravenous injection of 20 mg kg−1 pento-
barbital sodium, after which a catheter was inserted for 
urine sampling. Saline (0.9% NaCl in sterile water) was first 
administered via the great saphenous vein as a single bolus 
with a volume equivalent to that of the anticoagulants. 
Urine was collected over the following 30 min as a control 
specimen. Rats then received a bolus of argatroban       
(2 mg kg−1) via the same vein, after which urine was col-
lected over the following 30 min. Only rats that showed no 
gross hematuria were considered to be successful prepara-
tions and the next stage proceeded. Urine was centrifuged at 
3000×g for 10 min at 4°C. After removal of precipitates, 
urinary proteins were extracted by acetone precipitation [8] 
and subjected to quantitation by the Bradford method. 
Venous blood was collected by aspiration from the fem-
oral vein at three time points: 5 min after saline injection 
and 5 and 30 min after administration of anticoagulants. For 
the assessment of clotting time (CT), 25 µL of the blood 
sample was used. The remaining blood sample was imme-
diately transferred to a plastic tube containing 0.109 mol L1 
sodium citrate at a ratio of 1:9, gently mixed and centri-
fuged at 2000×g at 4°C for 10 min to obtain citrated plasma. 
Plasma was stored at −80°C until further analysis. 
Heparin (5 mg kg−1) was given intravenously to another 
group of rats by the same procedure as argatrabon experi-
ment described above.  
1.3  Determination of clotting time and activated par-
tial thromboplastin time  
CT was measured as previously reported [9]. Activated par-
tial thromboplastin time (APTT) determination was per-
formed using the External diagnostic reagent kit (Shanghai 
Taiyang Shengwu Technique Co., China) according to the 
manufacturer’s instructions.  
1.4  Protein digestion and peptide preparation 
Urine and plasma proteins were digested with trypsin 
(Trypsin Gold, Mass Spec Grade, Promega, USA) by FASP 
[10] using 10 kD Pall filtration devices (Pall Corporation, 
USA). Peptides were desalted using a 1 mL OASIS HLB 
cartridge (Waters, Milford, MA, USA) according to the 
manufacturer’s instructions. The eluate was dried via vac-
uum evaporation and stored at −20°C until LC-MS/MS 
analysis. 
1.5  LC-MS/MS analysis 
Lyophilized peptides were re-dissolved in 0.1% formic acid 
and subjected to chromatography using a Waters UPLC 
system. Peptides were separated on a 10-cm fused silica 
column packed in-house using ReproSil-Pur C18-AQ (3 µm 
resin). Elution was performed over a gradient of 5%–28% 
buffer B (0.1% formic acid, 99.9% ACN; flow rate, 0.3 µL 
min1) for 100 min. MS data were acquired using a Triple 
TOF MS system. Three technical replicate analyses were 
performed for each sample. 
1.6  Database searching and protein identification 
MASCOT server (version 2.4; Matrix Science, UK) was 
used for database searching against the Swissprot_Rat da-
tabase (data 05/03/2013, 9354 sequences). Search parame-
ters were set as follows: tryptic cleavages at only lysine or 
arginine with up to two missed cleavage sites allowed, fixed 
cysteine carbamidomethylation, variable glutamine deami-
dation and variable methionine oxidation. The precursor 
mass tolerance was set to 0.05 Da and the fragment mass 
tolerance to 0.05 Da. 
Scaffold (version Scaffold_4.0.4, Proteome Software Inc., 
Portland, OR, USA) was used to validate MS/MS based 
peptide and protein identifications. Peptide identifications 
were accepted if they could be established at greater than 
90.0% probability to achieve an FDR less than 0.1% by the 
Scaffold Local FDR algorithm [11]. Protein identifications 
were accepted if they could be established at greater than 
95.0% probability and contained at least two identified pep-
tides. Proteins that contained similar peptides and could not 
be differentiated based on MS/MS analysis alone were 
grouped to satisfy the principles of parsimony. 
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1.7  Label-free quantitation and statistical analysis  
The acquired spectra were loaded into the Progenesis soft-
ware application (version 2.5, Nonlinear UK (Progenesis 
LC-MS)) for label free quantification. The spectra were 
analysed according to the procedure described by Hauck et 
al. [12]. Following criteria were applied to increase the 
credibility of protein identification and quantification. First, 
proteins identified by a single peptide were excluded. Sec-
ond, we required that the direction of change in each animal 
be consistent and the fold change be 1.5 in at least one 
animal.  
1.8  Western blot analysis 
Urine and plasma proteins (20 µg/lane) were separated us-
ing 10% SDS-PAGE and blotted onto Immobilon PVDF 
transfer membranes (Millipore, USA) using the wet transfer 
system (Bio-Rad, USA), with 25 mmol L1 Tris-HCl, 192 
mmol L1 glycine, pH 8.3, and 15% methanol as the transfer 
buffer. All antibodies were purchased from Abcam (UK). 
For Western blot analyses, primary antibodies were used at 
1:1000 dilution and secondary antibodies (anti-rabbit HRP) 
at 1:10000 dilution. Blots were developed using ECL (En-
green Biosystem Co., Ltd., China). ECL results were 
scanned and analyzed using an ImageQuant 400TM Imager 
(GE Healthcare Life Sciences, USA) and the intensity of 
each protein band was quantified using Image J analysis 
software (National Institutes of Health, USA). 
2  Results 
2.1  Anticoagulants increased CT and APTT in rats 
CT and APTT were increased in both heparin- and 
argatroban-treated rats (Figure 1). APTT is the period 
required for clot formation in recalcified blood after contact 
activation and the addition of platelet substitutes. It is used 
to evaluate the intrinsic and screen for bleeding tendencies. 
CT is the period required for blood to clot in a glass tube. 
The prolonged CT and APTT indicate that the coagulation 
status is disrupted by the anticoagulants. 
2.2  Detection of changes in the protein composition of 
urine and plasma using label-free quantification 
On 1 D SDS-PAGE gel, urinary protein pattern did not 
show singnificant and consistent change before and after 
anticoagulants administration (Figure S1 in Supporting 
Information). 
The identical proteomic analysis approach was used to 
analyze the protein composition of rat urine and plasma 
samples before and after treatment with anticoagulants. 
Software Progenesis was used to perform label-free quanti-
fication. The details of criteria are described in Materials 
and methods. Briefly, for protein identification, the false  
 
 
Figure 1  Effects of intravenous bolus injections of argatroban and heparin on CT and APTT. A, APTT and CT increased in heparin treated group (n=6). *, 
P<0.005. The anticoagulants were administered 30 min after the injection of the isometric saline. The CT and APTT were assayed 5 min after saline injec-
tion (N) and 5 and 30 min after anticoagulant injection (5 and 30 min). B, APTT and CT increased in argatroban treated group (n=6). *, P<0.001. 
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positive rate was 1%. For quantification, only unique pep-
tides and proteins with at least two peptides were included. 
Besides, the direction of change in each animal should be 
consistent and the fold change should be 1.5 in at least one 
animal.  
LC-MS/MS analysis detected consistent heparin-induced 
changes in the levels of 27 proteins in urine but only three 
proteins in plasma (Table 1). There was no overlap between 
these groups of proteins. Consistent changes in the levels of 
62 proteins were detected in urine in response to treatment 
with argatroban, only one of which changed in plasma (Ta-
ble S1 in Supporting Information). The number of proteins 
identified in plasma was much smaller than the number de-
tected in urine (Table S2 in Supporting Information). These 
results indicate that changes in protein levels may be more 
sensitively detected using LC-MS/MS in urine than in 
plasma.  
2.3  Validation of changes in protein levels by Western 
blot 
Additional six animals were treated with anticoagulants to 
validate LC-MS/MS analysis of changes in the plasma and 
urine by Western blot. Plasma and urine samples were 
collected following the procedure described in Materials 
and methods, and transferrin and hemopexin were selected 
for validation. In accordance with changes in the levels of 
these proteins observed via the LC-MS/MS analysis, 
changes in the levels of both proteins in response to 
anticoagulant treatment were observed in urine but not in 
plasma (Figure 2).  
2.4  Functional analysis of the differential proteins 
Functional analysis of these differential proteins was 
performed by the Ingenuity Pathway Analysis (IPA) tool  
Table 1  Changed proteins in heparin treated groupa) 
Accession 









ITIH3_RAT 2.5 up N 
 
Inter-alpha-trypsin inhibitor heavy chain H3 
CO4_RAT 2.8 up N 
 
Complement C4 
IGG2C_RAT 3.1 up N 
 
Ig gamma-2C chain C region 
FIBB_RAT 2.1 up N 
 
Fibrinogen beta chain 
HEMO_RAT 2.6 up N 
 
Hemopexin 
FIBG_RAT 3.4 up N 
 
Fibrinogen gamma chain 
AFAM_RAT 3.7 up N 
 
Afamin 
APOA1_RAT 3.4 up N 
 
Apolipoprotein A-I 
FETUB_RAT 2.9 up N 
 
Fetuin-B 
CADH1_RAT 1.5 down N 
 
Cadherin-1 
ALBU_RAT 3.1 up N 
 
Serum albumin 
FETUA_RAT 2.9 up N 
 
Alpha-2-HS-glycoprotein 
APOH_RAT 2.4 up N 
 
Beta-2-glycoprotein 1 
EGF_RAT 2.3 down N 
 
Pro-epidermal growth factor 
FIBA_RAT 2.4 up N 
 
Fibrinogen alpha chain 
TRFE_RAT 2.5 up N 
 
Transferrin 
CO3_RAT 2.7 up N 
 
Complement C3 
UROK_RAT 3.5 down N 
 
Urokinase-type plasminogen activator 
DNAS1_RAT 2.3 down N 
 
Deoxyribonuclease-1 
IL4RA_RAT 1.8 down N 
 
Interleukin-4 receptor subunit alpha 
KLK7_RAT 2.0 down N 
 
Glandular kallikrein-7 
SPA3N_RAT 2.3 up N 
 
Serine protease inhibitor A3N 
KLK1_RAT 2.1 down N 
 
Kallikrein-1 
APOA4_RAT 3.3 up N 
 
Apolipoprotein A-IV 
MEP1A_RAT 5.1 down N 
 
Meprin A subunit alpha 
PLMN_RAT 3.7 up N 
 
Plasminogen 





1.6 down Plasma protease C1 inhibitor 
HBA_RAT N 
 
4.1 up Hemoglobin subunit alpha-1/2 
HBB1_RAT N 
 
3.9 up Hemoglobin subunit beta-1 
a) N indicates that the protein was not detected in the sample or failed to fulfil the quantitation criteria. 
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Figure 2  Western blot analysis of transferrin and hemopexin in urine and 
plasma. 20 µg/lane of urine or plasma proteins were loaded into gels and 
analysed using Western blot. Changes in the levels of transferrin and 
hemopexin were comparable with those detected by LC-MS/MS analysis. 
A, Heparin treated group. B, Argatroban treated group. C, Before antico-
agulants treated; T, after anticoagulants treated. 
(http://www.ingenuity.com/; Ingenuity Systems, USA). This 
analysis focused on the pathways and disease mechanisms 
in which the proteins are expected to be involved. 
As shown in Figure 3, the differential proteins of 
anticoagulants treated rats take part in acute phase response 
signaling, LXR/RXR activation, coagulation system, intr- 
insic prothrombin activation pathway and extrinsic prothr- 
ombin activation pathway. The proteins involved in coagul- 
ation pathway included F2, FGA, FGG, FGB, KLKB1, 
PLAU, PLG and SERPINA 1. 
3  Discussion 
Biological fluids such as blood, urine and CSF serve as 
common sources of biomarkers, of which plasma is most 
routinely used [13]. Although plasma perfuses all tissues of 
the body and theoretically it can collect all the information 
of disease biomarkers, the role of homeostatic mechanisms 
in eliminating changes in these biomarkers should not be 
ignored. Changes in blood biomarker levels are unlikely to 
persist long enough for detection because they are disturb-
ances of homeostasis. Because homeostasis helps to elimi-
nate or excrete changes in biomarker levels into urine, ex-
haled air, bile and perspiration, these places may serve po-
tential sources for biomarker discovery. 
There are exceptions, however, for example, it is better 
to detect biomarkers in plasma when they are continuously 
secreted into blood or have a long half-life. Moreover, bio- 
markers for acute illnesses such as acute-necrotizing pan-
creatitis and acute myocardial infarction are excreted into 
blood in large amounts in a short period of time. Plasma 
analysis may be more helpful to monitor progression of 
diseases.  
In this work, we demonstrated that more proteins could  
 
 
Figure 3  Functional analysis of the differential proteins via IPA. A, The Ingenuity Canonical Pathways in which the differential proteins of argatroban 
treated rats participated were phase response signaling, LXR/RXR activation, coagulation system and hepatic fibrosis/hepatic stellate cell activation. B, The 
Ingenuity Canonical Pathways in which the differential proteins of heparin treated rats participated were phase response signaling, LXR/RXR activation, 
coagulation system and intrinsic prothrombin activation pathway. 
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be identified in urine than in plasma. There are several pos-
sible reasons. Firstly, any change that is introduced into the 
blood either internally or externally tends to be cleared by 
the liver, kidney and/or other organs via a variety of mecha-
nisms to maintain the homeostasis of the blood. In contrast, 
urine is the place that most of the wastes in blood are 
dumped into, and thus tolerates changes to a much higher 
degree. Biomarkers are the measurable changes associated 
with a physiological or pathophysiological process. There-
fore, they are more likely to be magnified and detectable in 
urine than their counterparts in blood. 
Secondly, for proteomics and protein biomarker experi-
ments, high dynamic ranges of protein concentrations in hu-
man plasma lead to a tremendous analytical challenge. Plas-
ma proteins have a high dynamic range, spanning at least 109 
[14]. Albumin constitutes about half of the plasma proteins. 
In contrast, many potential biomarkers in plasma are at very 
low abundance. High-abundance proteins limit the identifica-
tion of low-abundance proteins by LC-MS/ MS.  
Thirdly, urine, as a filtrate of plasma, is relatively simple 
in composition, and the dynamic range of urinary proteins is 
about 106 [15]. Accumulated changes in urine composition 
are not likely to be masked, and some molecular species 
which are difficult to detect in blood may be detected in 
urine. Therefore, more proteins would be identified in urine 
with the same experimental sensitivity.  
Although methods such as multidimensional separation 
[16] can detect minor proteins or depletion of predominant 
proteins in plasma, they have several drawbacks. For exam-
ple, these approaches can introduce additional variability; 
moreover, because some peptides and proteins bind to cer-
tain high abundance proteins [17,18], the depletion strategy 
may lead to significant loss of information.   
While technological limitations prevented the detection 
of many components of urine in the past, more than 2300 
urinary proteins have recently been identified using high 
accuracy mass spectrometry [19], and technologies such as 
CE and SELDI-TOF MS have stimulated research into uri-
nary biomarkers. In addition, urinary proteins containing 
post-translation modifications such as glycosylation [2023] 
and phosphorylation [24,25] are potentially rich sources of 
disease biomarkers [26]. Moreover, profiling of urine pep-
tides and metabolites also reveals potential for the identifi-
cation of biomarkers for systemic diseases [2729]. Despite 
this evidence, the importance of urine serving as a bi-
omarker source remains underestimated. For example, we 
retrieved 316849 articles in a July 2013 search of PubMed 
using the keywords ((‘blood’ OR serum OR ‘plasma’) and 
‘biomarker’), compared with 33930 articles found using 
((‘urine’ OR ‘urinary’) and ‘biomarker’). In reality, the 
number of articles related to protein biomarkers in urine is 
no more than 450 in a manually organised database [30] 
(until June 2013, http://122.70.220.102/biomarker).  
There have already been some data, which indicates that 
certain urine biomarkers are of higher quality than those 
from plasma. For example, urine angiostatin levels have 
been shown to strongly correlate with the renal pathology 
chronicity index [31], and urinary levels of ADAM 12 and 
MMP-9 have been used as non-invasive biomarkers in iden-
tifying women at increased risk of developing breast cancer 
[32]. Moreover, elevation in urinary desmosine levels has 
been shown to be associated with COPD [33]. 
Because urine accumulates a significant number of 
changes, urine samples show a greater degree of variability, 
particularly in protein concentration and volume [34], even 
though levels of constitutive proteins remain stable [15,35]. 
Such variability can be readily normalized using levels   
of creatinine [36], cystatin C [37] and N-acetyl-β-D-     
glucosaminidase (NAG) [38]. A significant challenge for 
biomarker discovery in urine remains, which is discerning 
which changes in urine composition were caused by which 
systematic factor. Questions such as this can be addressed 
by large-scale population studies to survey normal varia-
tions in urine composition, which will lay the foundation for 
biomarker discovery in urine. 
Blood coagulation status is a critical physiological pa-
rameter, alterations of which can lead to embolism or 
haemorrhage. Because the use of blood samples to monitor 
coagulation status is harmful and invasive, particularly in 
patients with high risk of spontaneous bleeding, urine sam-
ples offer an alternative approach for monitoring the coagu-
lation state, which can greatly benefit these patients. 
In conclusion, using an identical proteomic analysis ap-
proach to profile the protein composition of rat urine and 
plasma samples before and after treatment with anticoagu-
lants, we found that changes in the abundance of many pro-
teins were consistently detected in urine samples but not in 
plasma. Urine may be the better source for biomarker dis-
covery, because it accumulates changes, and can be col-
lected noninvasively in large volumes. Faster and better 
biomarker discovery may lead to more accurate diagnosis 
and better health care. 
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Supporting Information 
Figure S1  Comparison of urinary proteins before and after drugs administration on SDS PAGE. Lanes 1, 3, 5, 7, 9, 11, proteins before drugs treated; lanes 
2, 4, 6, proteins after heparin treated; lanes 8, 10, 12, proteins after argatrabon treated. A total of 20 µg of protein was equally loaded in each lane (n=6 ani-
mals). 
Table S1  Changed proteins in argatroban treated group 
Table S2  Numbers of proteins identified in each animal 
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